IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) have been published in The Lancet ...
Despite the NHS’s founding principle that care should be based on clinical need, not ability to pay, Jake’s father is ...
Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia June 29, 2026 2:00 PM ...
GeneTAC® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1CARLSBAD, ...
The new facility strengthens Oman’s neuro-rehabilitation ecosystem following the success of the Aster Al Raffah Walk Again ...
Larimar submitted the module of a rolling biologics license application to the U.S. Food and Drug Administration for the ...
Larimar Therapeutics Inc. LRMR said Monday it has submitted the first module of a rolling Biologics License Application to ...
FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling ...
Design Therapeutics has its proprietary GeneTAC platform, which gives them a small-molecule way to target repeat-expansion ...
Presentations highlight clinical outcomes in pediatric PCQD subjects and translational evidence supporting tissue delivery and mitochondrial ...
Since my Friedreich ataxia (FA) diagnosis in 2008, when I was 11, I’ve been in and out of physical therapy. I’ve gone to lots of different outpatient facilities and worked with many therapists: ...
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma ASCO Guidelines provide recommendations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results